Neurocrine Biosciences Inc

Chart & Performance

D1W1MN

P/E

55.36

P/S

7.33

EPS

2.47

Div Yield, %

0.00%

Shrs. gr., 5y

1.15%

Rev. gr., 5y

33.13%

Revenues

1.89b

+26.76%

Net income

250m

+61.62%

CFO

390m

+14.88%

Earnings

Feb 05, 2025

Profile

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

URL

https://www.neurocrine.com/

IPO date

May 23, 1996

Employees

1,350

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	1,887,100 26.76%	1,488,700 31.34%	1,133,500 8.38%
Cost of revenue	604,700	487,000	342,400
Unusual Expense (Income)
NOPBT	1,282,400	1,001,700	791,100
NOPBT Margin	67.96%	67.29%	69.79%
Operating Taxes	82,400	59,400	11,800
Tax Rate	6.43%	5.93%	1.49%
NOPAT	1,200,000	942,300	779,300
Net income	249,700 61.62%	154,500 72.43%	89,600 -78.00%
Dividends
Dividend yield
Proceeds from repurchase of equity	65,300	44,700	27,500
BB yield	-0.49%	-0.38%	-0.33%
Debt
Debt current	170,100	169,400	16,500
Long-term debt	516,600	187,000	545,700
Deferred revenue		(32,800)
Other long-term liabilities	106,300	29,700	12,300
Net debt	(1,194,300)	(1,034,400)	(773,500)
Cash flow
Cash from operating activities	389,900	339,400	256,500
CAPEX	(28,300)	(16,500)	(23,400)
Cash from investing activities	(467,100)	(177,100)	(130,200)
Cash from financing activities	65,300	(234,300)	27,400
FCF	1,364,200	719,700	726,800
Balance
Cash	1,031,600	989,300	711,300
Long term investments	849,400	401,500	624,400
Excess cash	1,786,645	1,316,365	1,279,025
Stockholders' equity	(150,000)	(414,600)	(637,400)
Invested Capital	2,916,700	2,373,200	2,480,600
ROIC	45.37%	38.83%	32.73%
ROCE	46.35%	50.30%	42.92%
EV
Common stock shares outstanding	101,000	98,900	97,900
Price	131.76 10.31%	119.44 40.24%	85.17 -11.14%
Market cap	13,307,760 12.66%	11,812,616 41.67%	8,338,143 -11.05%
EV	12,113,460	10,778,216	7,564,643
EBITDA	1,303,700	1,017,300	802,000
EV/EBITDA	9.29	10.59	9.43
Interest	4,600	7,100	25,800
Interest/NOPBT	0.36%	0.71%	3.26%